CDA | Evidence Driven
CDA | Evidence Driven

Trisenox for Acute Promyelocytic Leukemia - Details

Details

Files
Generic Name:
Arsenic Trioxide
Project Status:
Complete
Therapeutic Area:
Acute Promyelocytic Leukemia
Manufacturer:
Lundbeck Canada Inc.
Brand Name:
Trisenox
Project Line:
Reimbursement Review
Project Number:
PC0033-000
Performance Metric:
N/A — Predated performance metrics
Strength:
1 mg/mL
Tumour Type:
Leukemia
Indications:
Acute Promyelocytic Leukemia
Funding Request:
For patients who were refractory to or relapsed from previous treatment and newly diagnosed APL patients who have received no prior treatment
Review Status:
Complete
Sponsor:
Lundbeck Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Arsenic (Trioxide) for APL - pERC Final Recommendation Final Recommendation February 18, 2014 View PDF
Arsenic (Trioxide) for APL - Final Clinical Guidance Report Guidance Reports February 18, 2014 View PDF
Arsenic (Trioxide) for APL - Final Economic Guidance Report Guidance Reports February 18, 2014 View PDF
Arsenic (Trioxide) for APL - pERC Initial Recommendation Initial Recommendation January 30, 2014 View PDF
Arsenic (Trioxide) for APL - PAG Feedback on Initial Recommendation Feedback February 18, 2014 View PDF
Arsenic (Trioxide) for APL - Patient Advocacy Group (LLSC) COI Declarations Feedback February 18, 2014 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : February 18, 2014